Ulixe files 12b-25 after acquisition-driven reporting delay
Ulixe Corp. notified the SEC it could not file its Form 10-Q for the quarter ended March 31, 2026 by the May 15, 2026 deadline due to delays completing its financial statements.
Rhea-AI Filing Summary
Ulixe Corp. notified the SEC it could not file its Form 10-Q for the quarter ended March 31, 2026 by the May 15, 2026 deadline due to delays completing its financial statements. The company discloses prior missing filings (Form 10-K for year ended July 31, 2025, Form 10-Q for September 30, 2025, and Form 10-K for December 31, 2025).
The filing states a change of control on June 13, 2025 when Ulixe One Corp. acquired approximately 89% of voting securities, a management transition, discontinuation of legacy software development, and consolidation of Ulixe Italy after a October 16, 2025 subsidiary acquisition and merger. Ulixe expects materially higher revenues and operating expenses for the quarter ended March 31, 2026 due to including Ulixe Italy, but has not provided quantitative estimates.
Positive
- None.
Negative
- None.
Insights
Late filings stem from post‑acquisition consolidation and delayed financial statements.
The company cites a change of control on June 13, 2025 and a subsidiary acquisition and merger on October 16, 2025, which required consolidation of Ulixe Italy into the group and delayed completion of the Form 10-Q for March 31, 2026.
Accounting teams will need to integrate foreign subsidiary results, revise prior-period filings, and complete disclosure of discontinued legacy development; subsequent filings should clarify the magnitude and timing of reported impacts.
Recent M&A and a management transition are the core drivers of reporting complexity.
The Registrant reports Ulixe One Corp.'s ~89% acquisition on June 13, 2025 and a related internal reorganization with Ulixe Italy on October 16, 2025. These events produced a change of control and a consolidation requirement for the fiscal year ended December 31, 2025.
Reported operational effects include discontinued legacy development and expected material increases in revenues and operating expenses for the quarter ended March 31, 2026; quantitative details are pending in the delayed filings.
Key Figures
Key Terms
Rule 12b-25 regulatory
change of control corporate
consolidation accounting
discontinued development operational
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did Ulixe (ULIX) file a Form 12b-25 for the March 31, 2026 10-Q?
Which prior filings has Ulixe (ULIX) not yet submitted?
How did Ulixe's corporate changes affect its March 31, 2026 results?
Who signed Ulixe's Form 12b-25 and how can the company be contacted?
Does Ulixe state whether the company will file the delayed 10-Q within the grace period?
AI-generated analysis. How Rhea-AI works. Not financial advice.